Soren M Gantt MD
Assistant Professor, Pediatrics, University of Washington School of Medicine
Join to View Full Profile
4800 Sand Point Way NESeattle, WA 98105
Phone+1 206-987-1909
Fax+1 206-987-3890
Dr. Gantt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Pediatric Infectious Diseases, 2003 - 2006- University of WashingtonResidency, Pediatrics, 2001 - 2003
New York University School of MedicineClass of 2001
Certifications & Licensure
WA State Medical License 2003 - 2015
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Start of enrollment: 2017 Mar 13
- CT18 Infant Influenza Priming Study in Vaccine Naive Infants Start of enrollment: 2018 Nov 01
Publications & Presentations
PubMed
- Prenatal Screening for CMV Primary Infection: A Cost-Utility Model.Gebrael El Hachem, Thomas G Poder, Catherine Mc Carey, Soren Gantt, Fatima Kakkar
BJOG. 2025-05-01 - Reinfection With Cytomegalovirus During Pregnancy: A Prospective Cohort Study in Canada.Juliette St-Georges, Safari Joseph Balegamire, Ariane Larouche, Suresh Boppana, Christian Renaud
Journal of Medical Virology. 2025-03-01 - 1 citationsA Geographically Weighted Cost-effectiveness Analysis of Newborn Cytomegalovirus Screening.Paul M Lantos, Soren Gantt, Mark Janko, Francois Dionne, Sallie R Permar
Open Forum Infectious Diseases. 2024-06-01
Press Mentions
- Babies and Toddlers Are Getting COVID-19 Vaccines in Montreal as Part of a Clinical TrialNovember 25th, 2021
UBC Faculty of Medicine Researchers Receive Nearly $14M in Federal Funding for COVID-19 ResearchJune 25th, 2020
Cytomegalovirus Vaccine Candidate Found to Be Safe & Immunogenic in First-in-Humans TrialOctober 11th, 2018- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
